Mounjaro vs Zepbound: Which Tirzepatide Is Right for You?
Same medicine, two names again. Here's which one your provider will reach for — and why.
Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly. Like Ozempic and Wegovy, they're the same drug with different FDA-approved uses.
| Mounjaro | Zepbound | |
|---|---|---|
| Active drug | Tirzepatide | Tirzepatide |
| FDA-approved for | Type 2 diabetes | Chronic weight management (and obstructive sleep apnea in obesity) |
| Mechanism | Dual GIP + GLP-1 | Dual GIP + GLP-1 |
| Max dose | 15 mg / week | 15 mg / week |
What tirzepatide does differently
Tirzepatide is a dual agonist — it activates two gut hormone receptors (GIP and GLP-1) instead of one. That dual action is associated with especially strong appetite and blood-sugar effects, and it's why tirzepatide has posted some of the highest weight-loss numbers in trials. We compare it directly to semaglutide in semaglutide vs tirzepatide.
Which one you'll be prescribed
If you have type 2 diabetes, Mounjaro is the on-label version. If your goal is weight management without diabetes, Zepbound is. Same molecule, same dosing — the label just reflects why you're taking it. Zepbound is also now approved for moderate-to-severe obstructive sleep apnea in adults with obesity.
Bottom line
Don't get hung up on the brand name. The clinically meaningful choice isn't Mounjaro vs Zepbound — it's tirzepatide vs semaglutide, and whether brand or a more affordable compounded version fits your situation.
Curious if tirzepatide is an option for you?
A licensed provider can review your information online and discuss affordable plans. Check your eligibility free.
Check Your Eligibility